Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE) | recruiting | — | 1,000 | Imperial College LondonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC(RePaIr-HN) | recruiting | Phase 3 | 214 | Universität des SaarlandesOTHER | 2 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | recruiting | Phase 1 | 110 | EpiBiologicsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07698886 | Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | recruiting | Phase 2 | 70 | KTH BiopharmaINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07668154 | A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07090070 | Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors(p53 RCT) | recruiting | N/A | 636 | University of British ColumbiaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC(FORTIFI-FLEX) | recruiting | Phase 2 | 160 | Bicara TherapeuticsINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05751512 | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | recruiting | Phase 3 | 180 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07281417 | Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma | recruiting | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT06163534 | A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | recruiting | — | 500 | Tempus AIINDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07801235 | HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC) | recruiting | N/A | 604 | King Hussein Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07690618 | Thermotherapy for Head and Neck Cancer Patients(TANCAP-I) | recruiting | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766226 | Online Sharing for Head & Neck Cancer Support | recruiting | N/A | 120 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer(CLARITY) | recruiting | — | 100 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07371234 | Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Rui YouOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794813 | Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer | recruiting | — | 40 | Yunnan Cancer HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796113 | Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | recruiting | Phase 2 | 24 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07058805 | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer(COMPORT) | recruiting | Phase 2 | 50 | Olgun ElicinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT06628570 | Screening Strategies Among High-risk Populations for Anal Cancer | recruiting | N/A | 500 | Lisa FlowersOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07392580 | Intralesional Chemotherapy (IC): Cisplatin + Epinephrine | recruiting | Phase 2 | 20 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787273 | Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Hefei Cancer Hospital of the Chinese Academy of SciencesNETWORK | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07781072 | Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07682831 | Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies | recruiting | N/A | 92 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07746258 | Testing Whether Skin Cancer Has Spread to Nearby Lymph Nodes(CECRE) | recruiting | N/A | 142 | Germans Trias i Pujol HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials